Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 49 | 2020 | 512 | 4.980 |
Why?
|
| Pancreas Transplantation | 16 | 2018 | 247 | 2.540 |
Why?
|
| Tissue Donors | 27 | 2018 | 207 | 1.770 |
Why?
|
| Graft Rejection | 18 | 2018 | 241 | 1.660 |
Why?
|
| Graft Survival | 27 | 2020 | 313 | 1.540 |
Why?
|
| Immunosuppressive Agents | 13 | 2016 | 241 | 1.260 |
Why?
|
| Islets of Langerhans | 7 | 2017 | 76 | 1.200 |
Why?
|
| Islets of Langerhans Transplantation | 6 | 2017 | 46 | 1.120 |
Why?
|
| Delayed Graft Function | 9 | 2020 | 33 | 1.090 |
Why?
|
| Tissue and Organ Procurement | 12 | 2018 | 99 | 0.970 |
Why?
|
| Antilymphocyte Serum | 5 | 2014 | 40 | 0.830 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 424 | 0.800 |
Why?
|
| Immunosuppression | 5 | 2014 | 120 | 0.750 |
Why?
|
| Kidney Failure, Chronic | 12 | 2018 | 543 | 0.700 |
Why?
|
| Pancreas | 6 | 2017 | 103 | 0.650 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 116 | 0.630 |
Why?
|
| Donor Selection | 4 | 2019 | 36 | 0.630 |
Why?
|
| Extracorporeal Circulation | 2 | 2011 | 13 | 0.620 |
Why?
|
| Antibodies, Neoplasm | 3 | 2009 | 15 | 0.600 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 205 | 0.590 |
Why?
|
| Humans | 64 | 2020 | 32969 | 0.540 |
Why?
|
| Antibodies, Monoclonal | 4 | 2009 | 241 | 0.530 |
Why?
|
| Living Donors | 3 | 2015 | 64 | 0.530 |
Why?
|
| Drug Compounding | 3 | 2017 | 36 | 0.510 |
Why?
|
| Regenerative Medicine | 6 | 2015 | 202 | 0.500 |
Why?
|
| Middle Aged | 34 | 2020 | 12203 | 0.480 |
Why?
|
| Kidney | 9 | 2020 | 523 | 0.470 |
Why?
|
| Renal Insufficiency | 2 | 2017 | 57 | 0.460 |
Why?
|
| Uremia | 1 | 2015 | 9 | 0.450 |
Why?
|
| Retrospective Studies | 26 | 2019 | 3708 | 0.440 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 13 | 0.430 |
Why?
|
| Female | 37 | 2020 | 20375 | 0.400 |
Why?
|
| Adult | 28 | 2020 | 9586 | 0.400 |
Why?
|
| Biopolymers | 1 | 2013 | 4 | 0.390 |
Why?
|
| Tissue Scaffolds | 7 | 2016 | 421 | 0.390 |
Why?
|
| Artificial Organs | 1 | 2013 | 13 | 0.380 |
Why?
|
| Nephrectomy | 5 | 2019 | 125 | 0.370 |
Why?
|
| Male | 36 | 2020 | 19754 | 0.360 |
Why?
|
| Extracellular Matrix | 4 | 2016 | 243 | 0.360 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2009 | 37 | 0.360 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 69 | 0.350 |
Why?
|
| Cadaver | 13 | 2018 | 165 | 0.350 |
Why?
|
| Thrombosis | 1 | 2012 | 81 | 0.340 |
Why?
|
| Thrombectomy | 1 | 2012 | 75 | 0.340 |
Why?
|
| Bioengineering | 4 | 2015 | 68 | 0.340 |
Why?
|
| Heart Arrest | 1 | 2011 | 40 | 0.330 |
Why?
|
| Anticoagulants | 1 | 2012 | 136 | 0.330 |
Why?
|
| Regeneration | 5 | 2016 | 170 | 0.320 |
Why?
|
| Animals | 15 | 2017 | 7599 | 0.310 |
Why?
|
| Pancreatectomy | 1 | 2008 | 25 | 0.280 |
Why?
|
| C-Peptide | 3 | 2018 | 30 | 0.280 |
Why?
|
| Young Adult | 8 | 2019 | 2738 | 0.270 |
Why?
|
| Survival Rate | 10 | 2018 | 895 | 0.260 |
Why?
|
| Alginates | 4 | 2017 | 52 | 0.250 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 82 | 0.250 |
Why?
|
| Treatment Outcome | 15 | 2017 | 3460 | 0.240 |
Why?
|
| Adolescent | 8 | 2019 | 3643 | 0.230 |
Why?
|
| Omentum | 2 | 2017 | 25 | 0.230 |
Why?
|
| Blood Group Incompatibility | 2 | 2016 | 11 | 0.230 |
Why?
|
| Postoperative Complications | 5 | 2018 | 828 | 0.230 |
Why?
|
| ABO Blood-Group System | 2 | 2016 | 21 | 0.230 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2017 | 58 | 0.220 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 2287 | 0.220 |
Why?
|
| Cold Ischemia | 2 | 2018 | 7 | 0.220 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 254 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2017 | 265 | 0.220 |
Why?
|
| Aged | 18 | 2019 | 10637 | 0.200 |
Why?
|
| Patient Selection | 5 | 2018 | 281 | 0.190 |
Why?
|
| Reoperation | 3 | 2019 | 260 | 0.190 |
Why?
|
| History, 20th Century | 2 | 2016 | 73 | 0.190 |
Why?
|
| Insulin | 4 | 2018 | 369 | 0.180 |
Why?
|
| Rabbits | 2 | 2014 | 193 | 0.180 |
Why?
|
| Tissue Engineering | 4 | 2016 | 659 | 0.180 |
Why?
|
| Risk Factors | 9 | 2018 | 4001 | 0.170 |
Why?
|
| Perfusion | 3 | 2013 | 74 | 0.160 |
Why?
|
| Time Factors | 9 | 2016 | 2195 | 0.150 |
Why?
|
| Prognosis | 7 | 2018 | 1547 | 0.150 |
Why?
|
| RNA | 1 | 2020 | 87 | 0.150 |
Why?
|
| Blood Glucose | 3 | 2017 | 495 | 0.150 |
Why?
|
| Child, Preschool | 6 | 2019 | 1282 | 0.150 |
Why?
|
| Hexuronic Acids | 3 | 2014 | 31 | 0.150 |
Why?
|
| Glucuronic Acid | 3 | 2014 | 31 | 0.150 |
Why?
|
| Angiography | 1 | 2019 | 80 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2018 | 2338 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 319 | 0.140 |
Why?
|
| Endarterectomy | 1 | 2018 | 6 | 0.140 |
Why?
|
| Mycophenolic Acid | 3 | 2008 | 41 | 0.140 |
Why?
|
| Death | 2 | 2009 | 53 | 0.140 |
Why?
|
| Renal Artery | 1 | 2018 | 47 | 0.140 |
Why?
|
| Gastrointestinal Tract | 3 | 2012 | 31 | 0.140 |
Why?
|
| North Carolina | 6 | 2018 | 1550 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 471 | 0.140 |
Why?
|
| Bioartificial Organs | 1 | 2017 | 25 | 0.130 |
Why?
|
| Insulin-Secreting Cells | 1 | 2017 | 53 | 0.130 |
Why?
|
| Incidence | 4 | 2018 | 1246 | 0.130 |
Why?
|
| Apolipoproteins | 2 | 2016 | 200 | 0.130 |
Why?
|
| Oxygen | 1 | 2017 | 144 | 0.130 |
Why?
|
| Cells, Immobilized | 1 | 2017 | 22 | 0.130 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 254 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 2 | 2014 | 49 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2020 | 75 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 34 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2016 | 61 | 0.120 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.110 |
Why?
|
| United States | 5 | 2017 | 4133 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2016 | 205 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1310 | 0.110 |
Why?
|
| Radiography, Interventional | 1 | 2014 | 32 | 0.110 |
Why?
|
| Age Factors | 6 | 2019 | 1202 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 183 | 0.110 |
Why?
|
| Immunocompetence | 1 | 2014 | 11 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 950 | 0.110 |
Why?
|
| Child | 4 | 2019 | 2478 | 0.110 |
Why?
|
| Ossification, Heterotopic | 1 | 2014 | 20 | 0.110 |
Why?
|
| Isoantibodies | 1 | 2014 | 12 | 0.100 |
Why?
|
| HLA Antigens | 1 | 2014 | 41 | 0.100 |
Why?
|
| Portal Vein | 1 | 2013 | 27 | 0.100 |
Why?
|
| Drainage | 1 | 2013 | 64 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 4 | 2018 | 310 | 0.100 |
Why?
|
| Pancreas, Artificial | 1 | 2013 | 4 | 0.100 |
Why?
|
| Transplantation, Homologous | 3 | 2009 | 151 | 0.100 |
Why?
|
| Creatinine | 5 | 2016 | 199 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2013 | 80 | 0.090 |
Why?
|
| African Americans | 2 | 2016 | 1425 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2014 | 250 | 0.090 |
Why?
|
| Warfarin | 1 | 2012 | 34 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2013 | 114 | 0.090 |
Why?
|
| Kidney Function Tests | 3 | 2018 | 107 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 42 | 0.090 |
Why?
|
| Aspirin | 1 | 2012 | 62 | 0.090 |
Why?
|
| Heparin | 1 | 2012 | 70 | 0.090 |
Why?
|
| Azathioprine | 1 | 2011 | 25 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 27 | 0.090 |
Why?
|
| Gout | 1 | 2011 | 14 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2011 | 1852 | 0.090 |
Why?
|
| General Surgery | 1 | 2012 | 86 | 0.090 |
Why?
|
| Length of Stay | 2 | 2014 | 329 | 0.090 |
Why?
|
| Warm Ischemia | 1 | 2011 | 9 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 1068 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 262 | 0.090 |
Why?
|
| Organ Preservation | 2 | 2009 | 37 | 0.080 |
Why?
|
| Ethnic Groups | 1 | 2013 | 474 | 0.080 |
Why?
|
| Inflammation | 2 | 2012 | 542 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2008 | 67 | 0.080 |
Why?
|
| Organ Transplantation | 1 | 2010 | 66 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2010 | 94 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 194 | 0.080 |
Why?
|
| Infant | 4 | 2019 | 1083 | 0.080 |
Why?
|
| Steroids | 1 | 2009 | 34 | 0.080 |
Why?
|
| Leukopenia | 1 | 2008 | 8 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 129 | 0.070 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 19 | 0.070 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2008 | 22 | 0.070 |
Why?
|
| Ganciclovir | 2 | 2008 | 23 | 0.070 |
Why?
|
| European Continental Ancestry Group | 2 | 2015 | 1163 | 0.060 |
Why?
|
| Mycoplasma hominis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cell Survival | 2 | 2017 | 281 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 292 | 0.050 |
Why?
|
| Arthritis, Infectious | 1 | 2005 | 26 | 0.050 |
Why?
|
| Hypertension | 1 | 2011 | 983 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2016 | 467 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 644 | 0.050 |
Why?
|
| Stem Cell Transplantation | 2 | 2015 | 212 | 0.050 |
Why?
|
| Transplantation Immunology | 2 | 2015 | 29 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 765 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 2 | 2014 | 111 | 0.050 |
Why?
|
| Brain Death | 2 | 2014 | 27 | 0.050 |
Why?
|
| Cytosine | 1 | 2002 | 10 | 0.050 |
Why?
|
| BK Virus | 1 | 2002 | 6 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 162 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2019 | 486 | 0.040 |
Why?
|
| African Continental Ancestry Group | 1 | 2002 | 363 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2014 | 99 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2002 | 68 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2012 | 183 | 0.040 |
Why?
|
| Antiviral Agents | 3 | 2008 | 108 | 0.040 |
Why?
|
| Intestines | 2 | 2010 | 60 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4065 | 0.040 |
Why?
|
| Registries | 2 | 2016 | 320 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 682 | 0.040 |
Why?
|
| Microspheres | 1 | 2017 | 44 | 0.030 |
Why?
|
| Capsules | 1 | 2017 | 14 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2016 | 9 | 0.030 |
Why?
|
| Organogenesis | 1 | 2016 | 18 | 0.030 |
Why?
|
| Social Support | 1 | 2017 | 183 | 0.030 |
Why?
|
| Waiting Lists | 2 | 2007 | 36 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 34 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 148 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 220 | 0.030 |
Why?
|
| Metaplasia | 1 | 2014 | 19 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 54 | 0.030 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2014 | 14 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 26 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 156 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 79 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2014 | 76 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 731 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2014 | 120 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 123 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 245 | 0.020 |
Why?
|
| Chickens | 1 | 2013 | 35 | 0.020 |
Why?
|
| Antigens | 1 | 2013 | 31 | 0.020 |
Why?
|
| Detergents | 1 | 2013 | 16 | 0.020 |
Why?
|
| Pressure | 1 | 2013 | 51 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2013 | 47 | 0.020 |
Why?
|
| Rats | 1 | 2017 | 1610 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 594 | 0.020 |
Why?
|
| Maryland | 2 | 2002 | 28 | 0.020 |
Why?
|
| Larynx | 1 | 2012 | 19 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 21 | 0.020 |
Why?
|
| Skin, Artificial | 1 | 2012 | 33 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 35 | 0.020 |
Why?
|
| Cell Transplantation | 1 | 2012 | 64 | 0.020 |
Why?
|
| Swine | 1 | 2012 | 216 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 497 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 84 | 0.020 |
Why?
|
| Gout Suppressants | 1 | 2011 | 4 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 78 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 220 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2529 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 188 | 0.020 |
Why?
|
| Corneal Transplantation | 1 | 2010 | 14 | 0.020 |
Why?
|
| Transplants | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 604 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2012 | 233 | 0.020 |
Why?
|
| Trachea | 1 | 2010 | 52 | 0.020 |
Why?
|
| Solutions | 1 | 2009 | 36 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 245 | 0.020 |
Why?
|
| Heart | 1 | 2010 | 185 | 0.020 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2009 | 6 | 0.020 |
Why?
|
| Asphyxia | 1 | 2009 | 8 | 0.020 |
Why?
|
| Infarction | 1 | 2009 | 6 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 976 | 0.020 |
Why?
|
| Suicide | 1 | 2009 | 20 | 0.020 |
Why?
|
| Ischemia | 1 | 2009 | 104 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 23 | 0.020 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 39 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 541 | 0.020 |
Why?
|
| Stem Cells | 1 | 2010 | 314 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 492 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2007 | 43 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 201 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2007 | 57 | 0.020 |
Why?
|
| Body Size | 1 | 2006 | 34 | 0.020 |
Why?
|
| Cause of Death | 1 | 2007 | 240 | 0.020 |
Why?
|
| Nephrons | 1 | 2006 | 10 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2006 | 147 | 0.010 |
Why?
|
| Heart Failure | 1 | 2012 | 761 | 0.010 |
Why?
|
| Ofloxacin | 1 | 2005 | 3 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 880 | 0.010 |
Why?
|
| Hip | 1 | 2005 | 15 | 0.010 |
Why?
|
| Edema | 1 | 2005 | 27 | 0.010 |
Why?
|
| Doxycycline | 1 | 2005 | 26 | 0.010 |
Why?
|
| Prednisone | 1 | 2005 | 63 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 51 | 0.010 |
Why?
|
| Pelvis | 1 | 2005 | 64 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 599 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 386 | 0.010 |
Why?
|
| Sirolimus | 1 | 2003 | 33 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 126 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1477 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 157 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 302 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 128 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 271 | 0.010 |
Why?
|
| Organophosphorus Compounds | 1 | 2002 | 32 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2002 | 1469 | 0.010 |
Why?
|